Navigation Links
Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)
Date:12/14/2009

DENVER, Dec. 14 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, and BG Medicine, Inc. (BGM), a Waltham, Massachusetts-based life sciences company, announced today a supply agreement whereby Corgenix will manufacture BGM Galectin-3 diagnostic products in enzyme-linked immunosorbent assay (ELISA) microtiter format exclusively for BG Medicine. BG Medicine is seeking regulatory clearance in the United States of the BGM Galectin-3 kit for clinical use in patients with heart failure.

Galectins are a family of proteins that play an important role in organ fibrosis, and galectin-3 has been shown to play an important role in the development and progression of heart failure in animal and human studies. Heart failure is a common, complex, and serious medical condition that affects approximately six (6) million people in the U.S. alone. Once diagnosed, the prognosis is poor, with approximately 50% surviving for more than five years.

"We are extremely pleased to extend our collaboration with BG Medicine to include the manufacturing of the BGM Galectin-3 kit," said Douglass Simpson, Corgenix President and Chief Executive Officer. "BG Medicine is bringing cutting edge technology and science to the cardiology market and we look forward to a long-term relationship."

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.

About BG Medicine

BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine discovers biomarkers and is developing its diagnostic product candidates using its proprietary, versatile, and scalable technology platform which integrates and automates the precise measurement, analysis, characterization and interpretation of proteins and metabolites collected from bodily fluids. For more information about BG Medicine, see www.bg-medicine.com.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect", or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

SOURCE Corgenix Medical Corporation


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09
2. Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program
3. Corgenix to Host Conference Call to Discuss Fiscal 2010 First Quarter Results
4. Corgenix Reports Financial Results for First Quarter of Fiscal 2010
5. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
6. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
7. Personalized Medicine - The Genomic Revolution in Cardiac Care
8. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
9. U.S. Preventive Medicine Acquires Specialty Disease Management
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Markets has announced the addition of the "Endodontic Supplies - Global Strategic ... , ... for Endodontic Supplies in US$ Thousand. The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , Latin America ... provided for the period 2015 through 2022. Also, a six-year historic analysis is ...
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX ... Nationwide Children,s Hospital signed a membership ... accelerate the development of new cures. ... representing over 57 million patients globally, biopharmaceutical companies ... together to improve protocol design, site selection, patient ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... gives development continuity to its innovative Unified Instance Manager architecture, meeting the ... addition, this new version optimizes the unattended auto-dialing system without agents, Presence ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan ... headquartered in Jefferson County, is announcing the launch of a charity drive to ... number of homeless women and children in Birmingham has grown steadily since the ...
Breaking Medicine News(10 mins):